Lynparza for breast cancer – pro
The oral PARP inhibitor olaparib is approved for the treatment of patients with recurrent ovarian cancer and a BRCA mutation, and it has been shown to provide clinically meaningful benefit among such patients. Olaparib has also been shown to have promising activity in patients with metastatic breast cancer and a germline BRCA mutation. The OlympiAD trial was designed to compare the efficacy and safety of olaparib with the efficacy and safety of standard therapy with single-agent chemotherapy of the physician’s choice among patients with HER2-negative metastatic breast cancer and a germline BRCA mutation. This study was a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (HER2)negative metastatic breast cancer who had received no more than two previous chemotherapy regimens for metastatic disease.
Among patients with HER2-negative metastatic breast cancer and a germline BRCA mutation, olaparib monotherapy provided a significant benefit over standard therapy; median progression-free survival was 2.8 months longer and the risk of disease progression or death was 42% lower with olaparib monotherapy than with standard therapy.
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. (1.1) • for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
The FDA has approved Lynparza and Avastin as the first drug combination to be used as a first-line maintenance therapy for some women with advanced ovarian cancer. (7/7/2020)
Mark Robson, M.D., Seock-Ah Im, M.D., Ph.D., Elżbieta Senkus, M.D., Ph.D., Binghe Xu, M.D., Ph.D., Susan M. Domchek, M.D., Norikazu Masuda, M.D., Ph.D., Suzette Delaloge, M.D., Wei Li, M.D., Nadine Tung, M.D., Anne Armstrong, M.D., Ph.D., Wenting Wu, Ph.D., Carsten Goessl, M.D., Sarah Runswick, Ph.D., and Pierfranco Conte, M.DOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation, NEJM June 4, 2017
NCCN, Breast Cancer 2020
LKynparza Prescribin INformation 2020